Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients.

Michalski JM, Lyden ER, Lee AJ, Al-Kadhimi ZS, Maness LJ, Gundabolu K, Bhatt VR.

Future Oncol. 2019 Jun 7. doi: 10.2217/fon-2019-0001. [Epub ahead of print]

PMID:
31170814
2.

Treatment patterns and outcomes of octogenarian patients with acute myeloid leukemia.

Bhatt VR, Shostrom V, Armitage JO, Gundabolu K.

Am J Hematol. 2019 Jun;94(6):E169-E172. doi: 10.1002/ajh.25464. Epub 2019 Apr 1. No abstract available.

PMID:
30883871
3.

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H.

J Natl Compr Canc Netw. 2018 Dec;16(12):1500-1537. doi: 10.6004/jnccn.2018.0088.

PMID:
30545997
4.

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.

Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Hendrie P, Lee AI, Lee JT, Mann J, McMahon B, Millenson MM, Morton C, Ortel TL, Ozair S, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Williams E, Zakarija A, Hammond L, Dwyer MA, Engh AM.

J Natl Compr Canc Netw. 2018 Nov;16(11):1289-1303. doi: 10.6004/jnccn.2018.0084.

PMID:
30442731
5.

Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States.

Bhatt VR, Shostrom V, Gundabolu K, Armitage JO.

Blood Adv. 2018 Jun 12;2(11):1277-1282. doi: 10.1182/bloodadvances.2018019125.

6.

Serendipitous Discovery of Factor VII Deficiency and the Ensuing Dilemma.

Umakanthan JM, Dhakal P, Gundabolu K, Koepsell SA, Baljevic M.

Maedica (Buchar). 2018 Mar;13(1):71-73.

7.

Factors associated with receipt of hematopoietic cell transplantation for acute lymphoblastic leukemia.

Manikkam Umakanthan J, Chen B, Gundabolu K, Bhatt VR.

Future Oncol. 2018 Jun;14(13):1253-1260. doi: 10.2217/fon-2017-0599. Epub 2018 May 1.

PMID:
29712491
8.

Atypical chronic myeloid leukemia: a rare entity with management challenges.

Dhakal P, Gundabolu K, Amador C, Rayamajhi S, Bhatt VR.

Future Oncol. 2018 Jan;14(2):177-185. doi: 10.2217/fon-2017-0334. Epub 2017 Dec 11. Review.

PMID:
29226717
9.

Anticoagulants Could Be a Victim of Enzalutamide.

Gundabolu K.

J Oncol Pract. 2017 Nov;13(11):730-731. doi: 10.1200/JOP.2017.027615. No abstract available.

PMID:
29125924
10.

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H.

J Natl Compr Canc Netw. 2017 Oct;15(10):1193-1207. doi: 10.6004/jnccn.2017.0157.

PMID:
28982745
11.

Initial therapy for acute myeloid leukemia in older patients: principles of care.

Bhatt VR, Gundabolu K, Koll T, Maness LJ.

Leuk Lymphoma. 2018 Jan;59(1):29-41. doi: 10.1080/10428194.2017.1323275. Epub 2017 Jun 2. Review.

PMID:
28573900
12.

Early mortality and overall survival of acute myeloid leukemia based on facility type.

Bhatt VR, Shostrom V, Giri S, Gundabolu K, Monirul Islam KM, Appelbaum FR, Maness LJ.

Am J Hematol. 2017 Aug;92(8):764-771. doi: 10.1002/ajh.24767. Epub 2017 Jun 1.

13.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H.

J Natl Compr Canc Netw. 2016 Dec;14(12):1572-1611.

PMID:
27956542
14.

Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.

Dhakal P, Rayamajhi S, Verma V, Gundabolu K, Bhatt VR.

Clin Appl Thromb Hemost. 2017 Jul;23(5):410-415. doi: 10.1177/1076029616675970. Epub 2016 Oct 26. Review.

PMID:
27789605
15.

Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia.

Khanal N, Bociek RG, Chen B, Vose JM, Armitage JO, Bierman PJ, Maness LJ, Lunning MA, Gundabolu K, Bhatt VR.

Am J Hematol. 2016 Nov;91(11):E468-E472. doi: 10.1002/ajh.24526. Epub 2016 Aug 29.

16.

An Algorithmic Approach to Management of Venous Thromboembolism.

Dhakal P, Gundabolu K, Bhatt VR.

Clin Appl Thromb Hemost. 2017 Sep;23(6):511-517. doi: 10.1177/1076029616652727. Epub 2016 Jun 5. Review.

PMID:
27268941
17.

Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia.

Goyal G, Gundabolu K, Vallabhajosyula S, Silberstein PT, Bhatt VR.

Ther Adv Hematol. 2016 Jun;7(3):131-41. doi: 10.1177/2040620716643493. Epub 2016 Apr 22. Review.

18.

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA.

J Natl Compr Canc Netw. 2015 Apr;13(4):424-34. Review.

PMID:
25870379
19.

The different faces of disseminated intravascular coagulation in solid tumors: how to identify and manage.

Gundabolu K.

Oncology (Williston Park). 2015 Feb;29(2):104, 106-7. No abstract available.

20.

Epidemiologic study of myelodysplastic syndromes in a multiethnic, inner city cohort.

Sridharan A, Jain R, Bachhuber MA, Yu Y, Ramesh Kh, Gundabolu K, Friedman EW, Verma AK.

Exp Hematol Oncol. 2014 Aug 23;3:22. doi: 10.1186/2162-3619-3-22. eCollection 2014.

21.

Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival.

Hu CY, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat TD, Suzuki M, Pullman J, Liu XS, Greally JM, Susztak K, Verma A.

Clin Cancer Res. 2014 Aug 15;20(16):4349-60. doi: 10.1158/1078-0432.CCR-14-0494. Epub 2014 Jun 10.

22.

Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity.

Msaouel P, Lam AP, Gundabolu K, Chrysofakis G, Yu Y, Mantzaris I, Friedman E, Verma A.

Haematologica. 2014 May;99(5):930-6. doi: 10.3324/haematol.2013.101949. Epub 2014 Feb 7.

23.

Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia.

Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S, Verma AK.

Am J Hematol. 2013 Nov;88(11):E245-9. doi: 10.1002/ajh.23529. Epub 2013 Sep 9.

24.

Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.

Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A, Singhal SB.

J Immunol. 2013 Mar 15;190(6):2966-75. doi: 10.4049/jimmunol.1202493. Epub 2013 Feb 13.

25.

miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.

Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A.

Blood. 2013 Apr 11;121(15):2875-81. doi: 10.1182/blood-2011-12-397067. Epub 2013 Feb 6.

26.

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A.

Cancer Res. 2011 Feb 1;71(3):955-63. doi: 10.1158/0008-5472.CAN-10-2933. Epub 2010 Dec 28. Erratum in: Cancer Res. 2011 Apr 1;71(7):2806. Mantzaris, Giannis [corrected to Mantzaris, Ioannis].

27.

Gum hypertrophy.

Gundabolu K, Kong G, Verma A.

CMAJ. 2009 Feb 17;180(4):471. doi: 10.1503/cmaj.080424. No abstract available. Erratum in: CMAJ. 2009 Apr 28;180(9):952.

28.

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

Zhou L, Nguyen AN, Sohal D, Ying Ma J, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat TD, Das B, Kapoun AM, Navas TA, Parmar S, Kambhampati S, Pellagatti A, Braunchweig I, Zhang Y, Wickrema A, Medicherla S, Boultwood J, Platanias LC, Higgins LS, List AF, Bitzer M, Verma A.

Blood. 2008 Oct 15;112(8):3434-43. doi: 10.1182/blood-2008-02-139824. Epub 2008 May 12.

Supplemental Content

Loading ...
Support Center